|
Market Closed -
NYSE
21:00:02 28/08/2026 BST
|
5-day change | 1st Jan Change | ||
| 1.140 USD | +1.79% |
|
+14.39% | -67.71% |
| 08-14 | ADC Therapeutics Balances LOTIS-5 Regulatory Risk With LOTIS-7 Opportunity, RBC Says | MT |
| 08-13 | ADC Therapeutics SA, Q2 2026 Earnings Call, Aug 13, 2026 |
Chart: Technical Analysis
Stock exchange
NYSE
ADCT 1.140 $
+1.79%
2.94M
$
| Markets | Price | Change | Volumes | ||
|---|---|---|---|---|---|
NYSE
| ADCT | 1.140USD | +1.79% | 2.94M $ | |
CBOE
| ADCT | 1.145USD | +2.23% | 42.27K $ |
Technical analysis trends
| Short Term | Mid-Term | Long Term | |
|---|---|---|---|
| Trend | Neutral | Bearish | Bearish |
| Resistance | 1.27 | 2.12 | 2.03 |
| Spread/Res. | -10.24% | -46.23% | -43.84% |
| Spread/Supp. | +18.74% | +18.74% | +14.39% |
| Support | 0.9601 | 0.9601 | 0.9966 |
MarketScreener's Technical Analysis Ratings
| Short Term Timing | |
|---|---|
| Middle Term Timing | |
| Long Term Timing | |
| RSI | |
| Bollinger Spread | |
| Unusual Volumes |
- Stock Market
- Stocks
- ADCT Stock
- Charts ADC Therapeutics SA
Select your edition
All financial news and data tailored to specific country editions
